| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | navitoclax:pluripotin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.061 | 0.09 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | -0.05 | 0.1 |
| mRNA | CIL55 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.1 |
| mRNA | CEP-701 | FIMM | pan-cancer | AAC | 0.2 | 0.1 |
| mRNA | QL-X-138 | GDSC1000 | pan-cancer | AAC | 0.05 | 0.1 |
| mRNA | Camptothecin | GDSC1000 | pan-cancer | AAC | -0.055 | 0.1 |
| mRNA | PI-103 | CTRPv2 | pan-cancer | AAC | 0.057 | 0.1 |
| mRNA | LAQ824 | GDSC1000 | pan-cancer | AAC | -0.055 | 0.1 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.057 | 0.1 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.055 | 0.1 |